IMPORTANT WARNING:
Tisagenlecleucel injection may cause a serious or life-threatening reaction called cytokine release syndrome (CRS). A doctor or nurse will monitor you carefully during your infusion and for at least 4 weeks afterwards. Tell your doctor if you have an inflammatory disorder or if you have or think you may have any type of infection now. You will be given medications 30 to 60 minutes before your infusion to help prevent reactions to tisagenlecleucel. If you experience any of the following symptoms during and after your infusion, tell your doctor immediately: fever, chills, shaking, cough, diarrhea, muscle or joint pain, tiredness, difficulty breathing, shortness of breath, confusion, nausea, vomiting, dizziness, or lightheadedness.
Tisagenlecleucel injection may cause severe or life-threatening nervous system reactions. If you experience any of the following symptoms, tell your doctor immediately: headache, restlessness, confusion, anxiety, difficulty falling asleep or staying asleep, uncontrollable shaking of a part of the body, loss of consciousness, agitation, seizures, pain or numbness in an arm or leg, loss of balance, difficulty understanding, or difficulty speaking.
Tisagenlecleucel injection is only available through a special restricted distribution program. A program called Kymriah REMS (Risk Evaluation and Mitigation Strategy) has been set up because of the risks of CRS and neurological toxicities. You can only receive the medication from a doctor and healthcare facility that participates in the program. Ask your doctor if you have any questions about this program.
Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with tisagenlecleucel. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer's website to obtain the Medication Guide.
IMPORTANT NOTICE:
Special Alert:
The Food and Drug Administration (FDA) has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies such as tisagenlecleucel injection. At this time, benefits still outweigh the risks, but your doctor will monitor you during and after receiving treatment. Talk to your doctor about any concerns you have regarding your treatment.